BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
Press Release|Articles|July 30, 2025
Camber Launches Prucalopride Tablets
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Prucalopride Tablets, a generic for Motegrity®, targeting chronic idiopathic constipation in adults.
- Chronic idiopathic constipation affects 10-17% of the global population, predominantly women and older adults.
Advertisement
Camber Pharmaceuticals, a leader in generic drug approvals and launches, is proud to add Prucalopride Tablets [proo-KAL-oh-pride] to its growing portfolio. Prucalopride Tablets are generic for Motegrity®.
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. CIC affects about 10-17% of the global population and is more commonly seen in women and older adults.
Prucalopride Tablets are available in 1 mg and 2 mg strengths in 30 count bottles.
To learn more about Prucalopride Tablets, please visit:
Advertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement